Ensysce Biosciences (ENSC) EBT (2018 - 2025)

Ensysce Biosciences (ENSC) has reported EBT for 8 consecutive years, with -$3.7 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, EBT fell 684.92% year-over-year to -$3.7 million in Q3 2025; TTM through Sep 2025 was -$11.1 million, a 39.4% decrease from a year earlier, with the FY2024 full-year figure at -$8.0 million, up 27.56% from the prior year.
• EBT was -$3.7 million for Q3 2025 at Ensysce Biosciences, down from -$1.8 million in the prior quarter.
• Over five years, EBT peaked at $640683.0 in Q3 2024 and troughed at -$16.9 million in Q3 2021.
• A 5-year average of -$3.8 million and a median of -$2.7 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 2623.52% in 2021 and surged 123.6% in 2024, its largest moves.
• Over 5 years, EBT stood at -$2.0 million in 2021, then plunged by 209.65% to -$6.3 million in 2022, then soared by 44.02% to -$3.5 million in 2023, then retreated by 2.48% to -$3.6 million in 2024, then decreased by 4.47% to -$3.7 million in 2025.
• The last three EBT figures came in at -$3.7 million (Q3 2025), -$1.8 million (Q2 2025), and -$2.0 million (Q1 2025), per Business Quant data.